Navigation Links
Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2017
Date:2/9/2017

SAN DIEGO, Feb. 9, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Dr. Scott Lee and Professor Tanja Kühbacher will present data on etrasimod (APD334) at the 12th Congress of European Crohn's and Colitis Organisation (ECCO) - Inflammatory Bowel Diseases 2017 on Friday, February 17. The conference is taking place February 15-18 at the CCIB Barcelona in Barcelona, Spain. The data are available in the Journal of Crohn's and Colitis, Volume 11, Issue Supplement 1.

The following abstracts will be presented:

Title: Safety and lymphocyte-lowering properties of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator, after dose escalation in healthy volunteers Session Type: Poster Presentation Poster Presentation Number: P369 Date: February 17 at 12:30pm CET Location: Poster Exhibition Area

Title: Immunomodulatory effects of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator Presenter: Scott Lee Session Type: Digital Oral Presentation Digital Oral Presentation Number: DOP077 Date: February 17 at 5:44pm CET Location: Room 111 – Level 1

Title: Pharmacology and safety of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator Presenter: Tanja Kühbacher Session Type: Digital Oral Presentation Digital Oral Presentation Number: DOP078 Date: February 17 at 5:50pm CET Location: Room 111 – Level 1

About Arena Pharmaceuticals We are a biopharmaceutical company focused on developing novel, small molecule drugs across a range of therapeutic areas. We have three primary proprietary investigational clinical programs: etrasimod (APD334) in Phase 2 evaluation for ulcerative colitis, APD371 entering Phase 2 evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH). Additionally, we have collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences Ltd. (Phase 2 candidate), and Boehringer Ingelheim International GmbH (preclinical candidate).

Our US operations are located in San Diego, California. Our primary clinical operations are located in Zug, Switzerland, and our commercial manufacturing for BELVIQ is located in Zofingen, Switzerland.

Forward-Looking Statements Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the upcoming presentations; and Arena's focus, primary programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact: Arena Pharmaceuticals, Inc. Kevin R. Lind, Chief Financial Officer klind@arenapharm.com 858.210.3636

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-three-upcoming-presentations-at-the-12th-congress-of-european-crohns-and-colitis-organisation---inflammatory-bowel-diseases-2017-300404708.html


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Arena Pharmaceuticals Completes Enrollment in Ralinepag Phase 2 Clinical Trial for Pulmonary Arterial Hypertension (PAH)
2. How These Biotechs Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
3. Arena Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
4. Arena Pharmaceuticals to Host Fourth Quarter and Full Year 2015 Financial Results and Corporate Update Conference Call and Webcast on Monday, February 29
5. Deloitte Corporate Finance LLC Advises The Marena Group, Inc. on its Recapitalization with The Riverside Company
6. Arena Helps Power IoT Revolution
7. Eisai and Arena Pharmaceuticals Announce FDA Acceptance of New Drug Application for Extended Release Formulation of Lorcaserin
8. Arena Pharmaceuticals to Present at Piper Jaffray 27th Annual Healthcare Conference
9. Arena Pharmaceuticals to Host Analyst & Investor Day on December 3rd
10. Arena Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update
11. Arena Pharmaceuticals to Host Third Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, November 10
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2018)... ... September 21, 2018 , ... In the ever-changing ... curve” and understand how the many changes affect their organizations. Toward that end, ... at the Westin Galleria Dallas to provide informative panel sessions and networking opportunities ...
(Date:9/15/2018)... ... 2018 , ... "As of Thursday, Sept. 13, 2018, Cedar Point, North Carolina, ... planning this Women of Influence tour with the knowledge that my home will have ... to hold onto my faith through this storm. So many lives are being affected ...
(Date:9/13/2018)... ... 13, 2018 , ... NCPDP announced today that its ... implementation of the NCPDP SCRIPT Standard Version 2017071 ahead of the January 1, ... by the industry as vital enhancements in improving patient safety, clinical decision-making, and ...
Breaking Medicine Technology:
(Date:9/24/2018)... (PRWEB) , ... September 24, 2018 , ... A groundbreaking ... of Plainfield, a new affordable assisted living community for Indianapolis seniors who need some ... located at 10480 Glasswater Lane, will serve seniors of all incomes. The new road ...
(Date:9/24/2018)... ... , ... As a leader in providing health, fitness and education professionals with ... movement or mobility and strength and live their lives better, Original Strength ... Coach/Instructor at Tucson Strength located in Tuscon, AZ and spends a great ...
(Date:9/24/2018)... ... ... A study recently published in STEM CELLS suggests unrestricted somatic stem cells (USSCs) ... of skin disorder called recessive dystrophic epidermolysis bullosa (RDEB). The stem cells also can ... estimated 25,000 people in the United States alone live with some form of RDEB, ...
(Date:9/23/2018)... ... September 23, 2018 , ... ... that specializes in working with healthcare, small business and non-profit organizations, announced ... Delivery System Reform Incentive Payment (DSRIP) Technical Assistance (TA) Program and the ...
(Date:9/22/2018)... ... ... Located on the fourth floor in the East Pavilion at Tampa General Hospital ... The 8,500 square-foot unit featuring 16 private rooms is the first of its kind ... TGH that provides excellent, innovative care,” said Andrew Molosky, MBA, FACHE, CHPCA, president and ...
Breaking Medicine News(10 mins):